Rationale and design of the Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnoea--RICCADSA trial.

Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708377 Publication Model: Print Cited Medium: Internet ISSN: 1651-2006 (Electronic) Linking ISSN: 14017431 NLM ISO Abbreviation: Scand Cardiovasc J Subsets: MEDLINE

Publication: 2015- : Abingdon, Oxford : Taylor & Francis
Original Publication: Oslo ; Boston : Scandinavian University Press, c1997-

Continuous Positive Airway Pressure*/adverse effects ; Continuous Positive Airway Pressure*/mortality ; Myocardial Revascularization*/adverse effects ; Myocardial Revascularization*/mortality; Cardiovascular Diseases/*prevention & control ; Coronary Artery Disease/*therapy ; Sleep Apnea, Obstructive/*therapy; Biomarkers/metabolism ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/mortality ; Coronary Artery Disease/complications ; Coronary Artery Disease/mortality ; Exercise Tolerance ; Heart Function Tests ; Humans ; Research Design ; Sleep Apnea, Obstructive/complications ; Sleep Apnea, Obstructive/mortality ; Sweden/epidemiology ; Time Factors ; Treatment Outcome

Rationale: Obstructive sleep apnoea (OSA) is common in coronary artery disease (CAD) and a possible cause of increased mortality. To date, there is a lack of randomized controlled trials to draw the conclusion that all CAD patients should be investigated for OSA and subsequently be treated with continuous positive airway pressure (CPAP).
Objective: The Randomized Intervention with CPAP in CAD and OSA (RICCADSA) trial is designed to address if CPAP treatment reduces the combined rate of new revascularization, myocardial infarction, stroke and cardiovascular mortality over a 3-year period in CAD patients with OSA. Secondary outcomes include cardiovascular biomarkers, cardiac function and maximal exercise capacity at 3-month- and 1-year follow-ups.
Patients and Methods: A sample of 400 CAD patients (100 non-sleepy OSA patients randomized to CPAP, 100 to non-CPAP; 100 sleepy OSA patients on CPAP, and 100 CAD patients without OSA) will be included. So far, 240 patients have been enrolled in the trial since December 31, 2005.
Conclusion: The RICCADSA trial will contribute to defining the impact of CPAP on prognosis of CAD patients with OSA.

0 (Biomarkers)

Date Created: 20080730 Date Completed: 20090313 Latest Revision: 20220309

20221213

10.1080/14017430802276106

18663661